VTAK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
VTAK is not a good buy right now. The stock is in a short-term downtrend with weakening momentum (negative and expanding MACD histogram) and it has slipped below a key support zone (~1.98). With no proprietary buy signals, no news catalysts, and continuing large losses despite revenue growth, the risk/reward is unfavorable for an impatient buyer looking for immediate upside.
Price action/trend: The stock fell -6.73% to 1.95 (closed), indicating strong near-term selling pressure. Momentum: MACD histogram is negative (-0.00281) and expanding lower, which is bearish and suggests downside momentum is strengthening. RSI: RSI(6) at ~32.5 is near oversold-but-not-a-reversal signal; it can stay weak in a downtrend. Moving averages: Converging MAs imply indecision, but current momentum favors bears. Levels: Pivot 2.146 (overhead). Immediate support S1 1.979 has effectively been breached (close 1.95). Next support S2 1.877. Resistance levels: 2.312 (R1), 2.414 (R2). A reclaim of ~1.98 and then 2.15 would be needed to improve the technical picture. Pattern-based probability: Similar-candlestick analysis suggests a 60% chance of -0.95% next day, modestly positive over 1 week (+0.49%) and 1 month (+1.74%), which is not compelling given current downside momentum.
Intellectia Proprietary Trading Signals
Q3 2025 revenue surged to $226K (+135.42% YoY), showing improving top-line traction off a small base.
Very high gross margin (92.04%), slightly improved YoY, suggests product economics are strong if the company can scale.
Upcoming earnings on 2026-02-12 (pre-market) could act as an event catalyst if results/forward commentary improve.
Bearish near-term technicals: sharp daily drop and MACD momentum worsening; price is below a key support area (~1.98).
Profitability remains very weak: Q3 2025 net income was -$2.251M and EPS -1.7 (EPS deterioration YoY), implying ongoing dilution/financing risk for a micro-cap.
No recent news flow to reverse sentiment, and no hedge fund/insider accumulation trend flagged recently.
Very small market cap (~$3.42M) typically increases liquidity and execution risk and can amplify drawdowns.
Latest reported quarter: 2025/Q3. Revenue increased to $226K (+135.42% YoY), indicating growth from a low base. However, losses remain heavy: net income -$2.251M and EPS -1.7 (EPS worsened significantly YoY). Gross margin remained extremely high at 92.04% (up 2.75% YoY), but operating costs are overwhelming the current revenue scale—overall, growth is improving but the trend in earnings quality is negative.
No analyst rating/price target data was provided, so there is no observable recent trend in Wall Street upgrades/downgrades or target changes. From a pro/con standpoint based on available fundamentals: Pros are accelerating revenue and very high gross margin; cons are worsening EPS, continued large losses, and weak price momentum.
